Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患肝炎的高危人。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在肝感染
中,重叠感染隐匿性HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性肝
人,TH1细胞活素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是慢性
肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性肝(CHC)患
α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙肝人,TH1细胞活素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的
素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人患
型
炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在染者中,重叠
染隐匿性HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性人,TH1细胞活素表达显著并与
免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖慢性
型
炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢性
(CHC)患者接受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在感染者中,重叠感染隐匿
HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,人,TH1细胞活素表达显著并与
免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是
(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的
(CHC)患者接受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在感染
中,重叠感染隐匿性HBV会影响干扰素的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性人,TH1细胞活素表达显著并与
免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是慢性
炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢性
(CHC)
受α干扰素包括派罗欣治疗时存在
功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙肝人,TH1细胞活
表达显著并与肝免
机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛抵抗和糖尿
是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品的人是患丙型肝炎的高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰的疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果,
性丙肝
人,TH1细胞
达
著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛抵抗和糖尿
是
性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无应答的危险因
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的性丙肝(CHC)患者接受α干扰
包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其达内容亦不代
本软件的观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品人是患丙型肝
高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰素疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,性丙肝
人,TH1细胞活素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是
性丙型肝
(CHC)中纤维
进展以及对抗
毒治疗无应答
危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若发现问题,欢迎向我们指正。
Intravenous drug users are in a high-risk category for hepatitis C.
静脉注射毒品人是患丙型肝炎
高危人。
In hepatitis C patients, occult HBV coinfection will reduce the response to interferon.
在丙肝感染者中,重叠感染隐匿性HBV会影响干扰素疗效。
Our findings show that in chronic hepatitis C, TH1 cytokines predominate and correlate to liver immunopathology.
研究结果显示,慢性丙肝人,TH1细胞活素表达显著并与肝免疫
理机制相关。
Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
此外,胰岛素抵抗和糖尿是慢性丙型肝炎(CHC)中纤维化进展以及对抗
毒治疗无
危险因素。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件
观点;若发现问题,欢迎向我们指正。